Loading...
Market
Story
Eli Lilly's Tirzepatide Zepbound Cuts Diabetes Risk by 94%, Achieves 23% Weight Loss
Aug 20, 2024, 11:00 AM
Eli Lilly's weight loss drug, Zepbound, featuring tirzepatide, has demonstrated significant efficacy in reducing the risk of developing type 2 diabetes. In a long-term study, the drug reduced the risk by 94% in adults with pre-diabetes and obesity or overweight, compared to a placebo. The three-year SURMOUNT-1 trial also showed that patients on the highest dose of Zepbound lost an average of 23% of their body weight over 176 weeks. These findings bolster the case for the drug's long-term use in managing obesity and preventing diabetes. The study's results have positively impacted Eli Lilly's stock performance, with shares seeing a pre-market increase.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 3 million • 25%
3 to 5 million • 25%
5 to 7 million • 25%
More than 7 million • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%